1. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer. (4th March 2018) Authors: Paplomata, Elisavet; Nahta, Rita Journal: Expert opinion on biological therapy Issue: Volume 18:Number 3(2018) Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. Issue 4 (1st February 2022) Authors: Schneider, Bryan P.; Jiang, Guanglong; Ballinger, Tarah J.; Shen, Fei; Chitambar, Christopher; Nanda, Rita; Falkson, Carla; Lynce, Filipa C.; Gallagher, Christopher; Isaacs, Claudine; Blaya, Marcelo; Paplomata, Elisavet; Walling, Radhika; Daily, Karen; Mahtani, Reshma; Thompson, Michael A.; Graha... Journal: Journal of clinical oncology Issue: Volume 40:Issue 4(2022) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). (August 2021) Authors: Mueller, Volkmar; Wardley, Andrew; Paplomata, Elisavet; Hamilton, Erika; Zelnak, Amelia; Fehrenbacher, Louis; Jakobsen, Erik; Curtit, Elsa; Boyle, Frances; Harder Brix, Eva; Brenner, Andrew; Crouzet, Laurence; Ferrario, Cristiano; Muñoz-Mateu, Montserrat; Arkenau, Hendrik-Tobias; Iqbal, Nayyer; A... Journal: European journal of cancer Issue: Volume 153(2021) Page Start: 223 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?. Issue 4 (24th October 2014) Authors: Paplomata, Elisavet; Nahta, Rita; O'Regan, Ruth M. Journal: Cancer Issue: Volume 121:Issue 4(2015) Page Start: 517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Systemic therapy for early‐stage HER2‐positive breast cancers: Time for a less‐is‐more approach?. Issue 4 (24th October 2014) Authors: Paplomata, Elisavet; Nahta, Rita; O'Regan, Ruth M. Journal: Cancer Issue: Volume 121:Issue 4(2015) Page Start: 517 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. (July 2014) Authors: Paplomata, Elisavet; O'Regan, Ruth Journal: Therapeutic advances in medical oncology Issue: Volume 6:Number 4(2014:Jul.) Page Start: 154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗